CN106906286B - Gene marker for diagnosing and treating tongue squamous carcinoma - Google Patents
Gene marker for diagnosing and treating tongue squamous carcinoma Download PDFInfo
- Publication number
- CN106906286B CN106906286B CN201710126589.3A CN201710126589A CN106906286B CN 106906286 B CN106906286 B CN 106906286B CN 201710126589 A CN201710126589 A CN 201710126589A CN 106906286 B CN106906286 B CN 106906286B
- Authority
- CN
- China
- Prior art keywords
- gage2d
- gene
- tongue squamous
- protein
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/18—Dental and oral disorders
Abstract
The invention belongs to the field of biological medicines, and discloses application of a GAGE2D gene as a diagnosis and treatment marker of tongue squamous cell carcinoma. Experiments prove that the expression of the GAGE2D gene in a normal tissue and a tongue squamous cell carcinoma tissue has obvious difference. According to the relevance of the GAGE2D gene and tongue squamous carcinoma, the GAGE2D gene can be used as a new molecular marker for clinically diagnosing the tongue squamous carcinoma, and can also be used as a new target of a tongue squamous carcinoma treatment drug.
Description
Technical Field
The invention relates to the fields of tumor diagnosis, treatment and prognosis prediction, in particular to a tumor diagnosis and prognosis prediction method by taking the detection of GAGE2D abnormality as a means; and a tumor therapeutic agent which activates GAGE2D gene or protein.
Background
Squamous cell carcinoma is the most common malignant tumor of head and neck, accounting for about 3% of the tumor of the whole body and 90% of the tumor of the oral cavity, while tongue carcinoma accounts for the first place of the incidence rate of squamous cell carcinoma of the oral cavity. Although the incidence of oral cancer has been on the decline in recent years in developed countries, the overall incidence is increasing. The majority of patients are male with age above 40, and the hair-growing parts are mostly on tongue, cheek, gum, etc. Tongue squamous carcinoma is a complex process with multiple factors, multiple steps and multiple stages, has complex and diverse etiology, and relates to physicochemical factors, microbial infection, heredity, ethnicity and the like. Although the etiology and related mechanisms of the tongue squamous carcinoma are always hot points of research and certain results are achieved, the tongue squamous carcinoma still has high mortality rate and poor prognosis. The reason for poor prognosis is that the diagnosis and treatment are not timely, tongue squamous carcinoma generally has no symptoms in the early stage, and patients often see a doctor due to clinical symptoms such as pain, ulcer which is difficult to heal, hemorrhage with unknown reasons, oral cavity or neck lump, and the like, and the disease condition is late and the survival rate is low. Early cases are treated timely, the 5-year survival rate can reach 85%, and once symptoms appear, the five-year survival rate is about 50%. In addition, the area of the focus is large, the surgical excision range is wide, and the postoperative life quality of the patient is seriously affected. The research on the biological behavior, occurrence and development mechanism of tongue squamous cell carcinoma is helpful for early diagnosis, prevention and treatment of diseases; the problem that effective molecular target genes are searched to reduce the death rate of tongue cancer is urgently needed to be solved; meanwhile, the method has wide clinical medical prospect and great scientific value.
The early diagnosis of oral cancer at the molecular level, especially at the genetic level, has become a trend in the field of oral cancer diagnosis, and the application numbers are: 201611136247.1, 201511009921.5, 201511009794.9, 201610245087.8, 201610277716.5, 201511009921.5 and 201610798012.2 patent documents all disclose gene markers which can be used for diagnosing oral cancer or squamous cell carcinoma. The present application is based on the prior art to find new biomarkers that can be used for tongue squamous carcinoma diagnosis.
Disclosure of Invention
One of the objects of the present invention is to provide a method for diagnosing tongue squamous carcinoma by detecting the difference in the expression of GAGE2D gene or protein.
The invention also aims to provide a method for predicting tongue squamous cell carcinoma prognosis by detecting the expression difference of GAGE2D gene or protein.
It is a further object of the present invention to provide a method for treating tongue squamous carcinoma by activating the GAGE2D gene or the GAGE2D protein.
The fourth purpose of the invention is to provide a method for screening the drug for treating tongue squamous carcinoma.
The fifth purpose of the invention is to provide a medicine for treating tongue squamous carcinoma.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides application of a product for detecting GAGE2D in preparing a tongue squamous cell carcinoma diagnosis tool.
Furthermore, the products for detecting the GAGE2D comprise products for detecting the expression level of GAGE2D genes.
Still further, the products for detecting GAGE2D include products capable of quantifying GAGE2D gene mRNA, and/or products capable of quantifying GAGE2D protein.
The product of the present invention for quantifying GAGE2D gene mRNA can exert its function based on a known method using a nucleic acid molecule: such as PCR, e.g., Southern hybridization, Northern hybridization, dot hybridization, Fluorescence In Situ Hybridization (FISH), DNA microarray, ASO methods, high throughput sequencing platforms, etc. The product can be used to conduct the assay qualitatively, quantitatively, or semi-quantitatively.
The nucleic acid contained in the above-mentioned products can be obtained by chemical synthesis, or by preparing a gene containing a desired nucleic acid from a biological material and then amplifying it using a primer designed to amplify the desired nucleic acid.
Further, the PCR method is a known method, for example, ARMS (Amplification Refractorymutation System) method, RT-PCR (reverse transcriptase-PCR) method, nested PCR method, or the like. The amplified nucleic acid can be detected by using a dot blot hybridization method, a surface plasmon resonance method (SPR method), a PCR-RFLP method, an in situ RT-PCR method, a PCR-SSO (sequence specific oligonucleotide) method, a PCR-SSP method, an AMPFLP (amplifiable fragment length polymorphism) method, an MVR-PCR method, and a PCR-SSCP (single strand conformation polymorphism) method.
The product capable of quantifying the mRNA of the GAGE2D gene comprises a primer for specifically amplifying the GAGE2D gene used in real-time quantitative PCR, and the sequence of the primer is shown as SEQ ID NO.1 and SEQ ID NO. 2.
The primers included in the product can be prepared by chemical synthesis, appropriately designed by referring to known information using a method known to those skilled in the art, and prepared by chemical synthesis.
The above-mentioned nucleic acids may further include a probe which can be prepared by chemical synthesis, appropriately designed by referring to known information using a method known to those skilled in the art, and prepared by chemical synthesis, or can be prepared by preparing a gene containing a desired nucleic acid sequence from a biological material and amplifying it using a primer designed for amplifying the desired nucleic acid sequence.
The product of the invention for quantifying GAGE2D protein can perform its function based on known methods using antibodies: for example, ELISA, radioimmunoassay, immunohistochemistry, Western blotting, etc. may be included.
The products of the invention for quantifying GAGE2D protein include antibodies or fragments thereof that specifically bind to GAGE2D protein. An antibody or fragment thereof of any structure, size, immunoglobulin class, origin, etc., may be used so long as it binds to the target protein. The antibodies or fragments thereof included in the assay products of the invention may be monoclonal or polyclonal. An antibody fragment refers to a portion of an antibody (partial fragment) or a peptide containing a portion of an antibody that retains the binding activity of the antibody to an antigen. Antibody fragments may include F (ab')2Fab', Fab, single chain fv (scfv), disulfide-bonded fv (dsfv) or polymers thereof, dimerized V regions (diabodies), or CDR-containing peptides. The products of the invention for quantifying GAGE2D protein can include isolated nucleic acids encoding the amino acid sequence of an antibody or encoding a fragment of an antibody, vectors containing the nucleic acids, and cells carrying the vectors.
Antibodies can be obtained by methods well known to those skilled in the art. For example, mammalian cell expression vectors that retain all or part of the target protein or incorporate polynucleotides encoding them are prepared as antigens. After immunizing an animal with an antigen, immune cells are obtained from the immunized animal and myeloma cells are fused to obtain hybridomas. The antibody is then collected from the hybridoma culture. Finally, a monoclonal antibody against the GAGE2D protein can be obtained by subjecting the obtained antibody to antigen-specific purification using the GAGE2D protein or a part thereof used as an antigen. Polyclonal antibodies can be prepared as follows: an animal is immunized with the same antigen as above, a blood sample is collected from the immunized animal, serum is separated from the blood, and then antigen-specific purification is performed on the serum using the above antigen. The antibody fragment can be obtained by treating the obtained antibody with an enzyme or by using sequence information of the obtained antibody.
Binding of the label to the antibody or fragment thereof can be carried out by methods generally known in the art. For example, proteins or peptides may be fluorescently labeled as follows: the protein or peptide is washed with phosphate buffer, a dye prepared with DMSO, a buffer, or the like is added, and the solution is mixed and left at room temperature for 10 minutes. In addition, labeling may be carried out using commercially available labeling kits, such as biotin labeling kit, e.g., biotin labeling kit-NH 2, biotin labeling kit-SH (Dojindo laboratories); alkaline phosphatase labeling kits such as alkaline phosphatase labeling kit-NH 2, alkaline phosphatase labeling kit-sh (dojindo laboratories); peroxidase labeling kits such as peroxidase labeling kit-NH 2, peroxidase labeling kit-NH 2(Dojindo Laboratories); phycobiliprotein labeling kits such as phycobiliprotein labeling kit-NH 2, phycobiliprotein labeling kit-SH, B-phycoerythrin labeling kit-NH 2, B-phycoerythrin labeling kit-SH, R-phycoerythrin labeling kit-NH 2, R-phycoerythrin labeling kit SH (dojindo laboratories); fluorescent labeling kits such as fluorescein labeling kit-NH 2, HiLyte Fluor (TM)555 labeling kit-NH 2, HiLyte Fluor (TM)647 labeling kit-NH 2(Dojindo Laboratories); and DyLight 547 and DyLight647(Techno Chemical Corp.), Zenon (TM), Alexa Fluor (TM) antibody labeling kit, Qdot (TM) antibody labeling kit (Invitrogen Corporation), and EZ-marker protein labeling kit (Funakoshi Corporation). For proper labeling, a suitable instrument can be used to detect the labeled antibody or fragment thereof.
As a sample of the detection product according to the present invention, a tissue sample or fluid obtained from a biopsy subject, for example, can be used. The sample is not particularly limited as long as it is suitable for the assay of the present invention; for example, it may comprise tissue, blood, plasma, serum, lymph, urine, serosal cavity fluid, spinal fluid, synovial fluid, aqueous humor, tears, saliva, or fractions or treated materials thereof.
In a specific embodiment of the invention, the sample is from a tissue of a subject.
Furthermore, the product for quantifying the GAGE2D gene or the GAGE2D protein can be a reagent for detecting the GAGE2D gene or the GAGE2D protein, can also be a kit, a chip, a test paper and the like containing the reagent, and can also be a high-throughput sequencing platform using the reagent.
The invention also provides a tool for diagnosing tongue squamous carcinoma, which can detect the expression level of GAGE2D gene.
Further, the means include reagents capable of quantifying GAGE2D gene mRNA, and/or reagents capable of quantifying GAGE2D protein.
Further, the reagent capable of quantifying the mRNA of the GAGE2D gene is a primer for specifically amplifying the GAGE2D gene used in real-time quantitative PCR, and the sequence of the primer is shown as SEQ ID NO.1 and SEQ ID NO. 2.
Further, the tool for diagnosing tongue squamous carcinoma includes, but is not limited to, a chip, a kit, a test paper, or a high throughput sequencing platform; the high-throughput sequencing platform is a special tool for diagnosing tongue squamous cell carcinoma, and with the development of a high-throughput sequencing technology, the construction of a gene expression profile of a person becomes very convenient and fast work. By comparing the gene expression profiles of patients with diseases and normal people, the abnormality of which gene is related to the disease can be easily analyzed. Therefore, the knowledge that the abnormality of GAGE2D gene is related to tongue squamous carcinoma in high-throughput sequencing is also included in the application of GAGE2D and is also within the protection scope of the present invention.
The number of amino acids recognized by the anti-GAGE 2D antibody or fragment thereof used in the detection product, diagnostic tool, and the like of the present invention is not particularly limited as long as the antibody can bind to GAGE 2D.
The present invention also provides a method for diagnosing tongue squamous carcinoma, comprising the steps of:
(1) obtaining a sample from a subject;
(2) detecting the expression level of GAGE2D gene or protein in the subject sample;
(3) correlating the measured expression level of GAGE2D gene or protein with the presence or absence of disease in the subject.
(4) When the expression level of the GAGE2D gene or protein is decreased as compared to the control, the subject is judged to have or be at risk of having tongue squamous cell carcinoma, or the patient with tongue squamous cell carcinoma is judged to have a relapse, or the patient with tongue squamous cell carcinoma is judged to have a poor prognosis.
The invention also provides a method of treating tongue squamous carcinoma, the method comprising activating a GAGE2D gene or a GAGE2D protein.
Further, the method comprises promoting the expression of the GAGE2D gene, or promoting the expression of GAGE2D protein or enhancing the activity of GAGE2D protein.
The invention also provides a screening method of tumor drugs, which can measure the effect of the tumor drugs on improving the tumor prognosis by measuring the expression level of GAGE2D gene or GAGE2D protein after adding test drugs to cancer cells or at a certain period after administering the test drugs to tumor model animals. More specifically, when the expression level of the GAGE2D gene or the GAGE2D protein is increased or restored to a normal level after the addition or administration of a test drug, the drug can be selected as a therapeutic drug for improving the prognosis of tumor.
The invention also provides a medicament for treating tongue squamous carcinoma, which comprises an activator of GAGE 2D.
The activator of GAGE2D of the invention is not limited as long as the activator can promote or enhance the expression or activity of GAGE2D or a substance involved in the upstream or downstream pathway of GAGE2D, and is a drug effective for treating tumors.
The invention also provides application of the activator in preparing a medicament for treating tongue squamous carcinoma.
Further, the activator comprises a GAGE2D gene, a GAGE2D protein, a promoting miRNA, a promoting transcriptional regulator, or a promoting targeted small molecule compound.
The activator can be used for supplementing the deletion or deficiency of endogenous GAGE2D protein and treating tongue squamous carcinoma caused by the lack of GAGE2D protein by improving the expression of GAGE2D protein. On the other hand, the protein can be used for enhancing the activity of GAGE2D protein, thereby treating tongue squamous carcinoma.
Other drugs that may be administered with the drug of the present invention are not limited as long as they do not impair the effect of the therapeutic or prophylactic drug of the present invention, and preferably, the drugs for treating or preventing tumors may include, for example, alkylating agents such as ifosfamide, cyclophosphamide, dacarbazine, temozolomide, nimustine, busulfan, procarbazine, melphalan, and ramustine, antimetabolites such as enocitabine, capecitabine, carmofur, cladribine, gemcitabine, cytarabine octadecyl phosphate (cytarabine ocsfate), tegafur-uracil, tegafur-oteracil potassium, floxuridine, hydroxyurea, fluorouracil, fludarabine, pemetrexed, pentixdine, mercaptopurine, and methotrexate, plant alkaloids such as irinotecan, zolpidoteracins, bortezomib, mitomycin, netorubicin, mitomycin, medroxyperazine, mitomycin, medroxyperazine, medetoriceptazocine, medetoposide, medroxyptericin, medroxyprinine, medroxyptericin, medroxyprogesterone, medetoriceptazocine, doxorubicin, mitomycin, doxorubicin, doxycycline, and another, medecin, and a, antibiotic, and a, as an, and an, as an, antibiotic, and an, antibiotic, as an, antibiotic, mitomycin, and an, as a, and an, as an, antibiotic, and an, antibiotic, and an drug.
The medicine of the present invention may be prepared into various preparation forms. Including, but not limited to, tablets, solutions, granules, patches, ointments, capsules, aerosols or suppositories for transdermal, mucosal, nasal, buccal, sublingual or oral use.
The route of administration of the drug of the present invention is not limited as long as it exerts the desired therapeutic or prophylactic effect, and includes, but is not limited to, intravenous, intraperitoneal, intraocular, intraarterial, intrapulmonary, oral, intravesicular, intramuscular, intratracheal, subcutaneous, transdermal, transpleural, topical, inhalation, transmucosal, dermal, gastrointestinal, intraarticular, intraventricular, rectal, vaginal, intracranial, intraurethral, intrahepatic, intratumoral. In some cases, the administration may be systemic. In some cases topical administration.
The dose of the drug of the present invention is not limited as long as the desired therapeutic effect or prophylactic effect is obtained, and can be appropriately determined depending on the symptoms, sex, age, and the like. The dose of the therapeutic agent or prophylactic agent of the present invention can be determined using, for example, the therapeutic effect or prophylactic effect on a disease as an index.
In the context of the present invention, "diagnosing squamous cell carcinoma" includes determining whether a subject has had squamous cell carcinoma, determining whether a subject is at risk for having squamous cell carcinoma, determining whether a patient having squamous cell carcinoma has relapsed and metastasized, determining responsiveness of a patient having squamous cell carcinoma to drug treatment, or determining a prognosis for a patient having squamous cell carcinoma.
As used herein, "treatment" encompasses treatment-related diseases or disease states in a mammal, such as a human, having the associated disease or disorder, and includes:
(1) preventing the occurrence of a disease or condition in a mammal, particularly when the mammal is susceptible to said disease condition but has not been diagnosed as having such a disease condition;
(2) inhibiting a disease or disease state, i.e., preventing its occurrence; or
(3) Alleviating the disease or condition, i.e., causing regression of the disease or condition.
The term "treatment" generally refers to the treatment of a human or animal (e.g., as applied by a veterinarian) wherein some desired therapeutic effect is achieved, e.g., inhibiting the progression of a condition (including slowing the progression, stopping the progression), ameliorating the condition, and curing the condition. Treatment as a prophylactic measure (e.g., prophylaxis) is also included. The use of a patient who has not yet developed a condition but who is at risk of developing the condition is also encompassed by the term "treatment".
The invention has the advantages and beneficial effects that:
the invention discloses a molecular marker for diagnosing tongue squamous cell carcinoma, which can be used for judging at the early stage of tongue squamous cell carcinoma and provides the survival rate of patients.
The therapeutic agent of the present invention comprising an activator of GAGE2D gene or protein can be used as a novel therapeutic agent for tongue squamous carcinoma.
Drawings
FIG. 1 shows a statistical graph of the differential expression of GAGE2D gene at the mRNA level using QPCR;
FIG. 2 shows a statistical chart of the detection of overexpression of GAGE2D gene at the protein level using Western blot;
FIG. 3 shows a statistical chart of the effect of GAGE2D gene overexpression on tongue squamous carcinoma cell proliferation.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings and examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. Experimental procedures without specific conditions noted in the examples, generally following conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the laboratory Manual (New York: Cold Spring harbor laboratory Press,1989), or according to the manufacturer's recommendations.
Example 1 screening for differentially expressed genes
1. Experimental Material
5 tongue squamous carcinoma tissue specimens were obtained from patients in oral and maxillofacial surgery, wherein 2 cases of highly differentiated squamous carcinoma, 2 cases of medium differentiated squamous carcinoma and 1 case of low differentiated squamous carcinoma; comprises 2 cases of men and 3 cases of women. Meanwhile, normal tissues in the area of >5cm around the cancer tumor of each cancer tissue are selected as self-control. All patients had no prior treatment with chemotherapy, radiotherapy, biotherapy or other tumor-specific therapies. After the material is taken, a part of tissue is immediately put into liquid nitrogen for storage and standby.
2. RNA extraction, cDNA Synthesis
Extracting total RNA by Trizol RNA reagent (Invitrogen company), and identifying the total RNA by an ultraviolet spectrophotometer (ND-1000, NanoDrop company) and agarose gel electrophoresis; mRNA was purified from RNeasy MinEluteCleanaup Kit according to the Qiagen instructions; the mRNA is reverse transcribed by Poly-A RNA Controlkit (Affymetrix company) to synthesize double-stranded cDNA, and is purified;
3. biotin-labeled cRNA hybridization
Taking cDNA as a template, synthesizing Biotin-labeled cRNA by in vitro transcription by using a MessageAmptM II-Biotin RNA Amplification Kit (Ambion company), and adding 5 Xfragmentation buffer solution into the purified cDNA according to an eukaryotic expression profile single-chip Amplification program of Affymetrix company to obtain fragmented cRNA with the size of 35-200 nt; after the preparation of the target is finished, preparing Hybridization solution by using a eukaryote Hybridization Control Kit (Affymetrix company), placing a chip injected with the Hybridization solution in a Hybridization furnace in a balanced manner, carrying out rotary Hybridization for 16h (Hybridization Oven 640, Affymetrix company) at 45 ℃ and 60r/min, and then cleaning and dyeing the chip in a washing workstation (Fluidics Station 450, Affymetrix company) provided by the Affymetrix company;
4. scanning and analysis
Applications of
The Scanner 3000(Affymetrix corporation) Scanner scans the image. Scanning the image first with
The Operating Software version1.4(GCOS 1.4, Affymetrix) Software performs image-to-signal value conversion into an original data file. The GCOS output was then further data analyzed using the innovative setNormalization method and Model-base expression index Model in software dChip 2006. From the P values detected in each chip, when the detected value Call value (AbsCall) of the dataset is absence of a (absent) or cutoff value m (margin), it is considered as not expressed, and only the dataset with the Abs Call value in presence of P (present) is used for further analysis.
5. Screening of genes differentially expressed in tissues
Screening for differentially expressed genes was performed using the Significant Analysis of Microarray Software (SAM) algorithm.
6. Results
859 differentially expressed genes are screened out by the chip. Compared with normal tissues, the expression of the tongue squamous carcinoma tissues is up-regulated by 517 genes, and the expression of the tongue squamous carcinoma tissues is down-regulated by 342 genes.
Example 2 validation of differentially expressed genes in Large samples
Based on the results of the initial screening of the chip, we selected the GAGE2D gene for large sample validation.
1. Sample collection
45 cases of each of the tongue squamous carcinoma tissues and the normal tissues were collected according to the method of example 1.
2. Validation at mRNA level
2.1 extraction of tissue RNA
The procedure is as in example 1.
2.2 reverse transcription
Primescript 1 was used for reverse transcriptionstThe strand cDNA synthesis kit comprises the following operation steps:
(1) the following reaction liquids were added to the microcentrifuge tube, as shown in table 1:
TABLE 1 reaction liquid
| Reagent | Dosage form |
| RNA | 2.0μg |
| dNTP | 1.0μl |
| Oligo(dT) | 2.0μl |
| Rnase free dH2O | Adding to 10.0. mu.l |
(2) Incubating at 70 deg.C for 5min, and rapidly cooling to 4 deg.C;
adding the following reaction reagents into a microcentrifuge tube to prepare a reaction system:
TABLE 2 preparation of the reaction System
Gently shaking, rapidly centrifuging, reacting at 42 deg.C for 1h, stopping reaction at 70 deg.C for 10min, cooling at 4 deg.C, and storing at-20 deg.C.
Using SYBP Premix Ex TapTMThe kit II is carried out in an Eppendorf Real-time PCR analyzer, and the specific operation is as follows:
(1) the following PCR reaction solutions were prepared on ice:
TABLE 3 preparation of PCR reaction solution
| Reagent | Dosage form |
| SYBR | 10.0μl |
| Forward primer | 1.0μl |
| Reverse primer | 1.0μl |
| cDNA | 2.0μl |
| ddH2O | 6.0μl |
| Total amount of | 20.0μl |
The primer sequences were designed as follows:
GAGE2D gene:
5’-CTCTACTGAGATTCATCTGTGT-3’(SEQ ID NO.1)；
5’-GTAGCGTCTTGGTCTAGG-3’(SEQ ID NO.2)
β-actin：
5’-GTGGGGCGCCCCAGGCACCA-3’(SEQ ID NO.3)；
5’-CTCCTTAATGTCACGCACGATTT-3’(SEQ ID NO.4)
(2) and the computer is used for executing the following programs: pre-denaturation at 95 ℃ for 3 min; denaturation at 95 ℃ for 15 s. Annealing at 59 ℃ for 20s, and extension at 72 ℃ for 20s, for 40 cycles.
The result is obtained by a relative quantitative method using formula 2-△ΔctAnd (4) calculating. The experiment was repeated 3 times.
△ct＝ct(A)-ct(β-actin)
△ Δ ct △ ct (experimental group) - △ ct (control group)
As shown in FIG. 1, the mRNA level of GAGE2D gene was significantly decreased in tongue squamous carcinoma tissues compared to normal tissues, and the difference was statistically significant (P < 0.05).
Example 3 GAGE2D Gene overexpression
1. Construction of GAGE2D Gene recombinant plasmid
(1) Amplifying the coding sequence of GAGE2D gene;
(2) designing an amplification primer;
(3) the amplified GAGE2D gene is connected to an expression vector pcDNA3.0 to construct a pcDNA3.0-GAGE2D recombinant expression vector.
2. Culture and transfection of tongue squamous carcinoma cells
2.1 cell culture
Human squamous cell carcinoma cell line HN4 was cultured in DMEM/F12 medium containing 10% FBS, 100U/mL penicillin and 100. mu.g/mL streptomycin. All cells were placed in a medium containing 5% CO2At 37 ℃ in a cell culture incubator.
2.2 transfection of cells
(1) Cells were plated at 2X 10 h before transfection5The cells were seeded in 6-well plates, DMEM/F12 medium was added, the cells were attached overnight, and transfection was performed when the cells reached 80-90% confluence.
(2) Diluting 1 μ g plasmid DNA in serum-free medium, and mixing gently; diluting 4 μ l Lipofectamine2000 in serum-free medium, mixing, and standing for 20min to obtain liposome complex.
(3) Adding 100 μ l liposome complex into tumor cells, mixing gently, and placing the cells at 37 deg.C containing 5% CO2Incubate for 6 hours.
(4) Cells were cultured for an additional 24 hours with 1ml growth medium containing 2 times the normal serum and antibiotic concentrations.
3. Extraction of Total cellular protein
The protein extraction procedure was performed according to the instructions of the EpiQuik whole cell extraction kit.
4. Western blot detection
Quantifying total protein by Brandford method, mixing with sample buffer solution, boiling for 5min, and cooling for 5 min; sampling 30pg protein to prepared 15% polyacrylamide gel, performing electrophoresis, setting the electrophoresis to be at a constant voltage of 80V, and increasing the voltage to 120V after seeing a Marker; taking out the gel after electrophoresis, and transferring for 50min at 100V by using a Bio. After the film transfer is finished, washing the film once by using 1xPBS, immersing the film in confining liquid, and standing overnight at 40 ℃; pouring off the blocking solution, adding Western washing solution for washing for 5-10min, and adding primary antibody shaker for hybridization at room temperature for 2 h; diluting with Western-derived secondary antibody diluent in blocking buffer solution according to a proper proportion, and incubating for 60 min; washing with the membrane-washing solution for 3 times, each for 10 min; protein expression was detected using ECL reagent development and fixation.
5. Statistical treatment
The grey values of the protein bands were analyzed by Image J software, with β -actin as an internal reference, and the grey values of the GAGE2D protein bands were normalized, the data were expressed as mean. + -. standard deviation, and statistically analyzed by SPSS13.0 statistical software, and the difference between the two was considered to be statistically significant when P <0.05 by t-test.
6. Results
As shown in FIG. 2, the expression level of GAGE2D protein was significantly increased in the cells transfected with pcDNA3.0-GAGE2D group compared to the cells transfected with pcDNA3.0 group, and the difference was statistically significant (P < 0.05).
Example 4 measurement of proliferation Capacity of tongue squamous carcinoma cells by overexpression of GAGE2D Gene
1. The method comprises the following steps:
tongue squamous carcinoma cells HN4 after 24 hours of transfection were seeded into 96-well cell culture plates at 2 × 10 per well3Setting a control group and an overexpression group at a cell/hole/200 mu l, and transfecting pcDNA3.0 empty vector by using cells of the control group; the over-expressed group was transfected with pcDNA3.0-GAGE 2D.
Cells were incubated at 37 ℃ with 5% CO2After 24 hours of incubation in the incubator again, the number of positive and negative Brd U-labelled cells was determined according to the instructions of the Brd U cell proliferation kit (Chemicon International) according to the following formula: the percentage of proliferating cells was calculated as 100% positive cells/(positive + negative cells), also called the cell proliferation rate.
2. Statistical method
The experiments were performed in 3 replicates, the results were expressed as mean ± sd, and were statistically analyzed using SPSS13.0 statistical software, with the difference between the two using the t-test, and considered statistically significant when P < 0.05.
3. Results
As shown in FIG. 3, the proliferation rates of the cells transfected with pcDNA3.0-GAGE2D were decreased compared to those transfected with pcDNA3.0, and the difference was statistically significant (P < 0.05). The above experimental results show that GAGE2D expression can inhibit tongue squamous carcinoma cell proliferation.
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
SEQUENCE LISTING
<110> Beijing, the deep biometric information technology GmbH
<120> Gene marker for diagnosing and treating tongue squamous carcinoma
<160>4
<170>PatentIn version 3.5
<210>1
<211>22
<212>DNA
<213> Artificial sequence
<400>1
ctctactgag attcatctgt gt 22
<210>2
<211>18
<212>DNA
<213> Artificial sequence
<400>2
gtagcgtctt ggtctagg 18
<210>3
<211>20
<212>DNA
<213> Artificial sequence
<400>3
<210>4
<211>23
<212>DNA
<213> Artificial sequence
<400>4
ctccttaatg tcacgcacga ttt 23
Claims (6)
1. Application of a product for specifically detecting GAGE2D in preparing a tool for diagnosing tongue squamous cell carcinoma.
2. The use of claim 1, wherein the product for specifically detecting GAGE2D comprises a product for detecting the expression level of GAGE2D gene.
3. Use according to claim 1 or 2, wherein the product specifically detecting GAGE2D comprises a product capable of quantifying GAGE2D gene mRNA and/or a product capable of quantifying GAGE2D protein.
4. The use according to claim 3, wherein the reagents capable of quantifying GAGE2D gene mRNA comprise primers for the specific amplification of GAGE2D gene used in real-time quantitative PCR, the primer sequences being shown in SEQ ID No.1 and SEQ ID No. 2; the reagents capable of quantifying GAGE2D protein include antibodies that specifically bind to GAGE2D protein.
Use of an activator of GAGE2D in the manufacture of a medicament for the treatment of tongue squamous carcinoma.
6. The use of claim 5, wherein the activator is capable of promoting or enhancing the expression or activity of GAGE2D or a substance involved in a GAGE2D upstream or downstream pathway.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710126589.3A CN106906286B (en) | 2017-03-03 | 2017-03-03 | Gene marker for diagnosing and treating tongue squamous carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710126589.3A CN106906286B (en) | 2017-03-03 | 2017-03-03 | Gene marker for diagnosing and treating tongue squamous carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106906286A CN106906286A (en) | 2017-06-30 |
| CN106906286B true CN106906286B (en) | 2020-03-31 |
Family
ID=59187722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710126589.3A Active CN106906286B (en) | 2017-03-03 | 2017-03-03 | Gene marker for diagnosing and treating tongue squamous carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106906286B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017013276A1 (en) * | 2015-07-22 | 2017-01-26 | Hospital Sant Joan De Deu | Immunotherapy for casr-expressing cancer (e.g. neuroblastoma) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120015904A1 (en) * | 2010-07-14 | 2012-01-19 | Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
-
2017
- 2017-03-03 CN CN201710126589.3A patent/CN106906286B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017013276A1 (en) * | 2015-07-22 | 2017-01-26 | Hospital Sant Joan De Deu | Immunotherapy for casr-expressing cancer (e.g. neuroblastoma) |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106906286A (en) | 2017-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106978480A (en) | Molecular diagnostic assay for cancer | |
| CN106906290B (en) | CDSN as diagnosis and treatment target of tongue squamous cell carcinoma | |
| CN112626207B (en) | Gene combination for distinguishing non-invasive and invasive non-functional pituitary adenomas | |
| CN107488737B (en) | Liquid biopsy kit for detecting peripheral blood TCR variable region coding gene and application thereof | |
| CN106947818B (en) | Molecular marker for diagnosis and treatment of colon adenocarcinoma | |
| CN106834496B (en) | PNLIPRP3 gene and application of expression product thereof in diagnosis and treatment of tongue squamous cell carcinoma | |
| CN106893778B (en) | Molecular marker for diagnosing and treating tongue squamous carcinoma | |
| CN107022635B (en) | ACARDL gene and application of expression product thereof in preparation of abdominal aortic aneurysm diagnosis and treatment product | |
| CN106244705B (en) | Application of the ERC1 in preparation diagnosis or treatment hypopharyngeal cancer tool | |
| CN106947819B (en) | Marker for diagnosis and treatment of colon adenocarcinoma | |
| CN106906286B (en) | Gene marker for diagnosing and treating tongue squamous carcinoma | |
| CN110577995B (en) | Diagnostic marker for male osteoporosis | |
| CN107034270B (en) | CLIC3 as diagnosis and treatment target of lung adenocarcinoma | |
| CN106947820B (en) | Application of VCAN in diagnosis and treatment of colon adenocarcinoma | |
| CN110577994B (en) | Product for non-invasive diagnosis of male osteoporosis | |
| CN108949986B (en) | Molecular marker-UPF 2 gene for diagnosing and treating cervical cancer and expression product thereof | |
| CN108949987B (en) | GPR19 as target for diagnosing and treating cervical cancer | |
| CN108624694B (en) | Application of CMC2 as cervical cancer diagnosis and treatment marker | |
| CN108753983B (en) | Marker for diagnosing and treating cervical cancer | |
| CN108841963B (en) | MLF1 gene for diagnosing and treating cervical cancer and application thereof | |
| CN106811532B (en) | Application of ACTA1 as tongue squamous carcinoma diagnosis and treatment marker | |
| CN107177674B (en) | SPHAR as diagnosis and treatment target for abdominal aortic aneurysm | |
| CN106381329B (en) | The diagnosis and treatment target of C18orf8 gene and its expression product as hypopharyngeal cancer | |
| CN106947821B (en) | Biomarkers for diagnosis and treatment of colon adenocarcinoma | |
| CN106011291B (en) | A kind of molecular marker of diagnosis and treatment hypopharyngeal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant after: Beijing Yang Shen biology information technology company limited Address before: 100080 Beijing city Haidian District Shanyuan Street No. 1 cubic court building room 3103 Applicant before: Beijing Yang Shen biology information technology company limited |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20200225 Address after: Room 2503, Qianshan building, building D2, Qingdao International Innovation Park Phase II, No. 1, Keyuan Weiyi Road, Laoshan District, Qingdao, Shandong Province Applicant after: Qingdao Yangshen biomedical Co., Ltd Address before: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant before: Beijing Yang Shen biology information technology company limited |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |